Archives

by in
Entry Author Date Location
San Diego Life Sciences Roundup: Receptos, Arena, NuVasive, & More 05/09/13 San Diego
From Assets to Zen: Building Successful Drug Hunting Relationships 04/22/13 San Diego
San Diego Life Sciences Roundup: Receptos IPO, Isis, Versant, & More 04/12/13 San Diego
San Diego’s Ambrx Working with Astellas to Develop Anti-Cancer Drugs 04/08/13 San Diego
San Diego Life Sciences Roundup: Illumina, Santarus, Accelrys, & More 01/18/13 San Diego
SD Life Sciences Roundup: Ambrx Gets Big Partner, GenMark, & More 06/21/12 National
Merck Bets $15M on Ambrx’s “Smart Bomb” Antibodies 06/18/12 San Diego
SD Biotech Roundup: Elevation Pharmaceuticals, BioSurplus, and More 05/17/12 San Diego
Targeted Cancer Drugs With Punch: The Next Big Class of Antibodies 05/16/12 National
Merck Returns to SD, Pouring $90M Into New Schultz-Led Institute 03/15/12 San Diego
Allozyne Raises More VC Cash, Looks to FDA Meeting After Poniard Deal Fizzles 12/23/11 Seattle
Celgene To Pump $45M into Quanticel to Discover Cancer Drugs, Gets Option To Acquire 11/04/11 San Francisco
Ambrx Grabs $24M Upfront in New Diabetes, Heart Failure Research Deal With Bristol-Myers 09/22/11 San Diego
Zymeworks Snags $187M Deal With Merck to Discover Multi-Pronged Antibodies 08/29/11 Seattle
Anaphore Snags $110M Deal With Mitsubishi Tanabe to Make Drugs for Immune Disorders 12/13/10 San Diego
Sutro Biopharma Grabs $36.5M in Venture Deal to Make “Biobetters” 11/17/10 San Francisco
Novartis-backed Genomics Institute Names Martin Seidel as New Director, Replacing Peter Schultz 10/05/10 San Diego
How Novartis Got Its Vaccines Groove Back, Intellikine Gets a Drug Development Deal, Ambrx CEO Departs, & More San Diego Life Sciences News 07/15/10 San Diego
Allozyne, After a Stealthy Year on a Slim Budget, Re-Emerges with MS Drug and Fat Pipeline 07/14/10 Seattle
Peter Schultz Exits Top Job at Genomics Institute of the Novartis Research Foundation 07/14/10 San Diego
Ambrx CEO Steve Kaldor Departs 07/12/10 San Diego
The 20-Year Outlook for San Diego Life Sciences: Sold Out? Not Anymore 03/15/10 San Diego
The 20-Year Future of San Diego Biotech, Coming March 31 03/09/10 San Diego
What Will San Diego’s Biotech Hub Look Like in 20 Years? Xconomy Event Takes Long View 02/16/10 San Diego
Biogen Idec CEO Stepping Down, Ambrx Focuses on Empowered Antibodies, Intellikine Testing First Drug Candidate, & More San Diego Life Sciences News 01/07/10 San Diego
Ambrx, Saying Thanks to its Rivals, Rides Wave of Interest in “Empowered” Antibodies 01/06/10 San Diego
Swine Flu Could Benefit Some Biomedical Companies, Local Biotechs Are Looking Healthier, Arena Happy With Obesity Drug Results, & More San Diego Life Sciences News 09/24/09 San Diego
Ambrx Strikes Deal With Wyeth (Soon-to-be Pfizer) to Make Antibody Drugs 09/18/09 San Diego
Intellikine, Stocked With Cash, Pushes Portfolio of Drugs Against Biology’s Hot Targets 08/18/09 San Diego
Wireless Medicine Gets $45M Booster Shot, Arena’s Weight-Loss Trial Underwhelms Wall Street, Venter’s Synthetic Genomics About to Ramp Up, & Other San Diego BizTech News 04/06/09 San Diego
Page 1 of 2 next page »

Xconomy Events Across the Network

The Napa Summit 2013: New Rules for Growth

San Francisco · 6/3/13

More Xconomy Events

Xconomy’s Most Popular

  1. Henri Termeer on Startups, Drug Prices, Getting Older (Part 1)
  2. Xconomy Opens in Texas, Expanding Roundup of Innovation Across U.S.
  3. Nine Lessons for Innovators from a Nobel Prize-Winning Psychologist
  4. Life After PowerPoint: Prezi Zooms Ahead in Digital Storytelling
  5. Do You Need an Extended Warranty? Do the Math, Says SquareTrade

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Mozy
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York, Boulder/Denver, Texas and beyond.

© 2007-2013, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Website development support from Andrew Koyfman with design support from Rob Hunter.